This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Berkshire Partners: Purchase of Rival Company (C)
El-Hage, Nabil N.; Baillargeon, Andre; Parks, StephenCase HBS-208025-EFinanceSupplements the (A) case.Starting at €5.74
-
Simon's Hostile Tender for Taubman (A)-(C), Teaching Note
El-Hage, Nabil N.Teaching Note HBS-208152-ETeaching Note for [205052], [205053], and [205062].Starting at €0.00
-
The a2 Milk Company, Teaching Note
Esty, Benjamin C.; Fisher, DanielTeaching Note HBS-719428-EStrategyTeaching note for case 719424.Starting at €0.00
-
United Technologies: Are the Parts Worth More Than the Whole
Esty, Benjamin C.; Fisher, DanielCase HBS-220018-EFinanceAfter spending more than 50 years creating a diversified industrial conglomerate that Fortune Magazine described as "arguably the most profitable conglomerate in America" in 2014, UTC's CEO Greg Hayes was under pressure from activist investors (Dan Loeb aStarting at €8.20
-
Impax Laboratories: Executing Accretive Acquisitions (B)
Esty, Benjamin C.; Fisher, DanielCase HBS-220031-EFinanceIExplores events after Impax announced the acquisition of a portfolio of generic pharmaceutical products from Teva in June 2016.Starting at €5.74
-
Gillette: Cutting Prices to Regain Share
Esty, Benjamin C.; Fisher, DanielCase HBS-720378-EStrategyAfter losing market share to low-priced competitors such as Harry's and Dollar Shave Club for several years, Gillette decided to fight back by launching new products and increasing advertising. When these efforts failed to stem the losses, Gillette decided to cut the prices on its razors and blades in April 2017. Bonnie Herzog, an equity analyst at Wells Fargo, must assess how the recently announced price cuts are likely to affect Gillette's earn...Starting at €8.20
-
TransDigm in 2017: The Beginning of the End or the End of the Beginning?
Esty, Benjamin C.; Fisher, DanielCase HBS-720422-EStrategyTransDigm was a highly acquisitive company that manufactured a wide range of highly engineered aerospace parts for both military and commercial customers. Over the ten years ending in 2016, its stock price had increase ten times, and both EBITDA and revenues had grown at compound annual rates in excess of 20%. But in early 2017, investors, customers, and government officials began to question the implementation, sustainability, and ethics of the ...Starting at €8.20
-
MoviePass: The "Get Big Fast" Strategy
Esty, Benjamin C.; Fisher, DanielCase HBS-719455-EStrategyIn August 2017, MoviePass dramatically lowered its subscription price from $50 per month to just $10 for up to one movie per day. The idea was to rapidly scale the business to the point where it could generate incremental revenue streams from related businesses (e.g., a share of ticket and concession revenues from theaters, advertising revenue from movie studios; and revenue from ride-sharing companies). Within two days, Moviepass had gotten 150k...Starting at €8.20
-
The a2 Milk Company
Esty, Benjamin C.; Fisher, DanielCase HBS-719424-EStrategyThe a2 Milk Company (a2MC) became the most valuable company listed on the New Zealand stock exchange in 2018 by capitalizing on a biochemical discovery related to the protein composition of cow's milk. Because many people find the A1 protein difficult to digest, and that protein may be related to other health problems (e.g., diabetes), a2MC sells dairy products containing the A2 protein only primarily in Australia and China. With sales of NZ$730 ...Starting at €8.20
-
Impax Laboratories: Executing Accretive Acquisitions (A)
Esty, Benjamin C.; Fisher, DanielCase HBS-220030-EFinanceImpax Laboratories was a technology-based pharmaceutical company that used a "dual platform" strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the early morning of June 21, 2016, the firm issued a press release announcing it was buying a portfolio of generic drugs from Teva for $586 million in cash. The leadership team (CEO, CF...Starting at €8.20